During the February 9, 2023 Executive Business Meeting, Senate Judiciary Committee reported Interagency Patent Coordination and Improvement Act of 2023, Prescription Pricing for the People Act of 2023, Preserve Access to Affordable Generics and Biosimilars Act, and more.
It is hard to predict whether a given bill will gain traction, but when the Senate Judiciary Committee reports out five bipartisan bills targeting pharmaceutical patents and pricing, it.
2021 saw several important milestones in the biosimilars space, including the much anticipated first interchangeable designations by FDA and the approval of the first ophthalmology.